Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1999-05-25
2000-05-09
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424 854, 424 856, 514 2, 514 21, 530351, A61K 3702
Patent
active
060604506
ABSTRACT:
Methods of treating autoimmune disorders, such as multiple sclerosis, are disclosed. The methods employ administration of interferon-tau (IFN.tau.) in a therapeutically-effective dose.
REFERENCES:
patent: 4997646 (1991-03-01), Hansen et al.
patent: 5019382 (1991-05-01), Cummins, Jr.
patent: 5372808 (1994-12-01), Blatt et al.
patent: 5906816 (1999-05-01), Soos et al.
Arnason, B.G.W., and Reder, A.T., "Interferons and Multiple Sclerosis," Clin. Neuropharmacol. 17(6):495-547 (1994).
Bazer, F.W., and Johnson, H.M., "Type I Conceptus Interferons: Maternal Recognition of Pregnancy Signals and Potential Therapeutic Agents," Am. J. Reproduc. Immunol. 26:19-22 (1991).
Brod, S.A., and Burns, D.K., "Suppression of Relapsing Experimental Autoimmune Encephalomyelitis in the SJL/J Mouse by Oral Administration of Type I Interferons," Neurology 44:1144-1148 (1994).
Brod, S.A., et al., "Modification of Acute Experimental Autoimmune Encephalomyelitis in the Lewis Rat by Oral Administration of Type I Interferons," J. Interfer. & Cytokine Res. 15:115-122 (1995).
Duquette, P., et al., "Interferon b--1b is Effective in Relapsing-Remitting Multiple Sclerosis. I. Clinial Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial," Neurology 43:655-661 (1993).
Pontzer, C.H., et al., "Antiproliferative Activity of a Pregnancy Recognition Hormone, Ovine Trophoblast Protein-1," Cancer Res. 51:5304-5307 (1991).
Sierra, A., et al., "Multiple Sclerosis: Secretion of IL-2, IFN-T, and PGE.sub.2 in Mononuclear Cell Cultures Stimulated with PHA, and Effect of these Cytokines on Oligondendroglial Cells," Neurologia 7(9):247-252 (1992) [Translation].
Soos, J.M., et al., "The Novel Type I Interferon Tau Development and Superantigen Reactivation of Experimental Allergic Encephalomyelitis in Mice without Associated Toxicity," Faseb J. for Exper. Biol. 9(4) :A1025 (1995).
Soos, J.M., and Johnson, H.M., "Type I Interferon Inhibition of Superantigen Stimulation: Implications for Treatment of Superantigen-Associated Disease," J. Interferon and Cytokine Res. 15:39-45 (1995).
Abramsky, O., et al., "Suppressive Effect of Pregnancy on MS and EAE" in Experimental Allergic Encephalomyelitis: A Useful Model For Multiple Sclerosis, Alan R. Liss, Inc., 150 Fifth Ave., New York, NY, pp. 399-406, 1984.
Kim, C., et al., "Reduction of Lupus Nephritis in MLR//pr mice by a Bacterial Superantigen Treatment", J. Exp. Med. 174(1431-1437 (1991).
Pontzer, C.H., et al., "Structure/Function Studies with Interferon Tau: Evidence for Multiple Active Sites" J. Interferon Res. 13:133-144 (1994).
Soos, J.M., and Johnson, H.M., "Type I Interefron Inhibition of Superantigen Activity: Immplications for Treatment of Immunity", The Faseb J. (Abstracts) 8(15):4412 (1994).
Soos, J.M., and Johnson, H.M., "Type I Interferon Inhibition of Superantigen Stimulation: Implications for Treatment of Superantigen-Associated Disease", J. Interferon and Cytokine Res. 15:39-45 (1995).
Johnson Howard Marcellus
Schiffenbauer Joel
Soos Jeanne M.
Moezie F. T.
University of Florida
LandOfFree
Method for treatment of autoimmune diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of autoimmune diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of autoimmune diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1065132